Gilead Sciences is a global biopharma company with diverse portfolio and is known for its infectious disease drug portfolio.
- In July 2020, US FDA approved Brexucabtagene autoleucel (developed by Kite Pharma), sold under the brand name Tecartus™; is a CAR-T cell therapy and is the first cell-based gene therapy approved by the US FDA for the treatment of mantle cell lymphoma in adults.
- In Apr 2020, U.S. FDA approved Immunomedics’s Trodelvy™ (sacituzumab govitecan-hziy), for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. Trodelvy is the first ADC approved by the FDA specifically for relapsed or refractory metastatic TNBC.
- In Oct 2017, U.S. FDA approved Axicabtagene ciloleucel (developed by Kite Pharma), sold under the brand name Yescarta™, a CAR-T therapy as a second-line treatment for diffuse large B-cell lymphoma that has failed conventional treatment.
- In July 2014, U.S. FDA approved idelalisib (Zydelig tablets) for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab. The FDA has also granted Zydelig accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL).
Page 1 of 2
